NO20083916L - Proteasom- eller UPS-inhibitor for behandling av infeksjoner med influensavirus - Google Patents

Proteasom- eller UPS-inhibitor for behandling av infeksjoner med influensavirus

Info

Publication number
NO20083916L
NO20083916L NO20083916A NO20083916A NO20083916L NO 20083916 L NO20083916 L NO 20083916L NO 20083916 A NO20083916 A NO 20083916A NO 20083916 A NO20083916 A NO 20083916A NO 20083916 L NO20083916 L NO 20083916L
Authority
NO
Norway
Prior art keywords
proteasome
influenza virus
treatment
virus infections
infections
Prior art date
Application number
NO20083916A
Other languages
English (en)
Norwegian (no)
Inventor
Ulrich Schubert
Oliver Planz
Stephan Ludwig
Original Assignee
Virologik Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virologik Gmbh filed Critical Virologik Gmbh
Publication of NO20083916L publication Critical patent/NO20083916L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20083916A 2006-02-17 2008-09-12 Proteasom- eller UPS-inhibitor for behandling av infeksjoner med influensavirus NO20083916L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006008321A DE102006008321A1 (de) 2006-02-17 2006-02-17 Mittel zur Behandlung von Infektionen mit Influenzaviren
PCT/EP2007/051510 WO2007093635A2 (de) 2006-02-17 2007-02-16 Proteasom- oder ups-inhibitor zur behandlung von infektionen mit influenzaviren

Publications (1)

Publication Number Publication Date
NO20083916L true NO20083916L (no) 2008-11-14

Family

ID=38110461

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083916A NO20083916L (no) 2006-02-17 2008-09-12 Proteasom- eller UPS-inhibitor for behandling av infeksjoner med influensavirus

Country Status (15)

Country Link
US (1) US20090074716A1 (zh)
EP (1) EP1988972A2 (zh)
JP (1) JP2009526824A (zh)
KR (1) KR20080096826A (zh)
CN (1) CN101384301A (zh)
AU (1) AU2007216478A1 (zh)
BR (1) BRPI0708073A2 (zh)
CA (1) CA2642751A1 (zh)
DE (1) DE102006008321A1 (zh)
IL (1) IL193466A0 (zh)
MX (1) MX2008010569A (zh)
NO (1) NO20083916L (zh)
RU (1) RU2008137140A (zh)
WO (1) WO2007093635A2 (zh)
ZA (1) ZA200806413B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2467144A1 (en) * 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
CN110093322B (zh) * 2019-05-14 2020-05-15 中国农业科学院兰州兽医研究所 Mg132作为疫苗生产增效剂及稳定剂的应用
CN110812472B (zh) * 2019-11-19 2022-10-21 福建医科大学 E3泛素连接酶stub1在抑制乙型肝炎病毒复制中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033654A1 (en) * 1998-12-04 2000-06-15 University Of Maryland Biotechnology Institute Use of protease inhibitors to modulate cellular pathways, immunity and therapies associated therewith
AU2003208275A1 (en) * 2002-01-27 2003-09-02 Viromics Gmbh Trojan inhibitors, method for the production and use thereof
DE10391147D2 (de) * 2002-04-05 2005-02-17 Viromics Gmbh Mittel zur Behandlung von Flaviviridae-Infektionen
WO2004004749A1 (en) * 2002-07-03 2004-01-15 Charite - Universitätsmedizin Berlin Proteaseome inhibitors for the treatment of herpesviridae infected individuals
DE10300222A1 (de) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen
WO2005007141A2 (en) * 2003-07-11 2005-01-27 Proteologics, Inc. Ubiquitin ligase inhibitors and methods related thereto

Also Published As

Publication number Publication date
US20090074716A1 (en) 2009-03-19
CN101384301A (zh) 2009-03-11
BRPI0708073A2 (pt) 2011-05-17
CA2642751A1 (en) 2007-08-23
ZA200806413B (en) 2010-02-24
AU2007216478A1 (en) 2007-08-23
MX2008010569A (es) 2008-10-09
JP2009526824A (ja) 2009-07-23
RU2008137140A (ru) 2010-03-27
DE102006008321A1 (de) 2007-08-30
EP1988972A2 (de) 2008-11-12
IL193466A0 (en) 2009-08-03
KR20080096826A (ko) 2008-11-03
WO2007093635A3 (de) 2007-12-13
WO2007093635A2 (de) 2007-08-23

Similar Documents

Publication Publication Date Title
NO20085243L (no) Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
BR112018068565A2 (pt) combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos
ECSP045223A (es) Composiciones farmacéuticas para inhibidores de proteasa viral de la hepatitis c
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
EA202092456A3 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
CR11499A (es) Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c
ECSP088258A (es) Inhibidores de serina proteasas
GT201300077A (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas
EA201201235A1 (ru) Комбинации фармацевтических агентов в качестве ингибиторов репликации hcv
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
NZ592705A (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
EA201490254A1 (ru) Комбинированное лечение гепатита с
BR112015007616A2 (pt) inibidores de mek no tratamento de doenças por vírus
WO2007101710A8 (en) Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
ATE511514T1 (de) Phosphadiazin-hcv-polymerase-hemmer vom typ iv
CR20110267A (es) Tratamiento de transtornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo[]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
AR062453A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
EP3501532A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application